Memorial Sloan Kettering has one of the nation’s largest clinical trial programs for people with liver cancer.
We’re on the hunt for answers, continuously conducting research to find agents that improve how we care for people with primary liver disease. Sometimes we can offer you therapies that are not available elsewhere through our clinical trials.
Studying Liver Cancer Stages
Our researchers are evaluating ways of diagnosing and staging primary liver tumors by studying the value of new imaging techniques, including:
- volumetric CT, which produces visual representations in three dimensions
- dynamic contrast-enhanced MRI, a technique using rapid imaging and a contrast material that, when combined with ultrasound, makes certain organs, blood vessels, or tumors easier to see
- nuclear imaging, which produces images of different parts of the body
The Fibrolamellar-Hepatocellular Carcinoma Consortium
We’re determined to improve treatment options for people with the primary liver cancer fibrolamellar-hepatocellular carcinoma (FLL-HCC). We lead a collaborative initiative with colleagues at Johns Hopkins University and the University of California, San Francisco, with the aim of:
- promoting awareness about FLL-HCC within the cancer community
- developing new therapies for the disease
- pooling information on patients in order to document trends in diagnosis, treatment, and survival
Liver Cancer Clinical Trials
Clinical trials test new drugs and drug combinations, surgical techniques, diagnostic technologies, and strategies for preserving quality of life for people undergoing treatment. Our experts can help determine if clinical trials are right for you. The following liver cancer clinical trials at MSK are currently enrolling new patients. To learn more about a study, choose from the list below.
